Anti-mouse Cripto-1 Protein (CR-1)



GENTAUR • Belgium : + 32 2 7325688 • France : 01 43250150 • Italy : 02 36006593 • Germany : +49 241 6085 13140

TEL: +32 16 58 90 45

Fax :+ 32 16 50 90 45

GENTAUR Europe

GENTAUR France

tel 01 43 25 01 50

fax01 43 25 01 60

9, rue Lagrange

75005 PARIS

FRANCE

GENTAUR Italy

tel 02 36 00 65 93

fax 02 36 00 65 94

20135 MILANO

ITALY

GENTAUR Germany

tel +49 241 6085 13140

fax +49 241 6085 33033

Forckenbeckstraße 6,

D-52074 Aachen

GERMANY

Product Details: Anti-mouse Cripto-1 Protein (CR-1). IgG fraction (monoclonal)


Basic Information

Product ID:	MA-771-5
Product Name:	Anti-mouse Cripto-1 Protein (CR-1). IgG fraction (monoclonal)
Unit:	100µg
Price:	245 Euro
Availability:	Available
Category:	Growth Factors, Cytokines, Receptors and their Antibodies
Subcategory:	Monoclonal Antibodies (Cancer Antigens)


Product Details

Description:	IgG fraction from mouse monoclonal antibody (clone 8B10/H8) obtained by immunization of mice with Cripto-1 protein from mouse (27 kDa). The IgG fraction was purified using Protein G-Sepharose.
Isotype:	IgG1
Biological Activity:	This antibody can be used for ELISA assay (1:8,000). It recognizes mouse Cripto protein. Cripto-1 is a signaling protein and member of the epidermal growth factor protein family. It plays an important role during early embryonic development. It has also a role in tumor development, induces cell proliferation, reduces apoptosis and increases cell migration. Cripto-1 is released or shed from expressing cells and may serve as marker gene in the early to mid-progressive stages of a variety carcinomas.
Formulation:	Solution at 0.5 mg/mL in PBS
Storage Conditions:	Store at -20oC
Stability:	Stable for at least one year. Avoid repeated freezing and thawing.
Temperature:	-20°C
References:	Strizzi, L. et. al. (2004) J. Cell. Physiol. 201, 266 - 276. Adamson, E.D. et. al. (2002) J. Cell. Physiol. 190, 267 - 278. Minchiotti, G. et. al. (2002) Gene 287, 33 - 37. Persico, M.G. et. al. (2001) Biochim. Biophys. Acta 1552, 87 - 93 Salomon, D.S. et. al. (2000) Endocr. Relat. Cancer 7, 199 - 226.